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Background: Heart failure (HF) is the most common cause of morbidity and mortality in developed countries. Here,
we identify biologically relevant transcripts that are significantly altered in the early phase of myocardial infarction
and are associated with the development of post-myocardial infarction HF.
Methods: We collected peripheral blood samples from patients with ST-segment elevation myocardial infarction
(STEMI): n = 111 and n = 41 patients from the study and validation groups, respectively. Control groups comprised
patients with a stable coronary artery disease and without a history of myocardial infarction. Based on plasma
NT-proBNP level and left ventricular ejection fraction parameters the STEMI patients were divided into HF and
non-HF groups. Microarrays were used to analyze mRNA levels in peripheral blood mononuclear cells (PBMCs)
isolated from the study group at four time points and control group. Microarray results were validated by RT-qPCR
using whole blood RNA from the validation group.
Results: Samples from the first three time points (admission, discharge, and 1 month after AMI) were compared with the
samples from the same patients collected 6 months after AMI (stable phase) and with the control group. The greatest
differences in transcriptional profiles were observed on admission and they gradually stabilized during the follow-up. We
have also identified a set of genes the expression of which on the first day of STEMI differed significantly between patients
who developed HF after 6 months of observation and those who did not. RNASE1, FMN1, and JDP2 were selected for
further analysis and their early up-regulation was confirmed in HF patients from both the study and validation groups.
Significant correlations were found between expression levels of these biomarkers and clinical parameters. The receiver
operating characteristic (ROC) curves indicated a good prognostic value of the genes chosen.
Conclusions: This study demonstrates an altered gene expression profile in PBMCs during acute myocardial infarction
and through the follow-up. The identified gene expression changes at the early phase of STEMI that
differentiated the patients who developed HF from those who did not could serve as a convenient tool contributing to
the prognosis of heart failure.Background
Genome-wide gene expression profiling is an extensively
used strategy for discovering new potential biomarkers for
diagnosis/prediction of disease severity [1,2] and identifi-
cation of novel drug targets [3]. Transcriptome analysis
has been applied successfully to numerous complex dis-
eases including cardiovascular disorders [4,5].* Correspondence: mgora@ibb.waw.pl; atka@ibb.waw.pl
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unless otherwise stated.Coronary heart disease (CHD) is one of the major
causes of heart failure (HF), the predominant cause of
morbidity and mortality in developed countries. HF is a
major public health concern whose incidence is continu-
ing to increase. While advances in the management of
HF have improved patient outcomes, it remains the
leading hospital admission diagnosis in elderly patients
and carries a 5-year mortality rate as high as 50% [6].
The HF prevalence in the general population in the de-
veloped countries is estimated to be in the range of 0.4%
to 2% [7]. Thus, it can be assumed that 6.5 to 10 millionl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the general population and the advances in the treat-
ment of cardiovascular disease (CVD) have led to a
gradual growth of the HF cohort, increasing the percent-
age of patients requiring hospitalization and intensive
medical care.
Acute myocardial infarction (AMI) induces left ven-
tricular (LV) remodeling, a process that can influence
ventricular functions and survival outcomes. LV remod-
eling is directly implicated in the post-infarction devel-
opment of ventricular dilatation, a predictive sign for a
future HF [8]. The progression to HF after AMI is multi-
factorial and depends on the extent of the myocardial
damage at the time of the index event, recurrent ische-
mia and the development of myocardial stunning and hi-
bernation, LV remodeling, and chronic neuroendocrine
stimulation. Robust early prediction of LV remodeling
and the development of HF after AMI is challenging and
may potentially be improved by the identification of
novel transcriptional biomarkers associated with these
processes [9].
Several biomarkers are known to be associated with
LV remodeling and the development of HF [10]. Among
the most important ones are natriuretic peptides, in par-
ticular B-type natriuretic peptide (BNP) and N-terminal
pro-brain natriuretic peptide (NT-proBNP). They have a
fair prognostic value in patients with acute coronary
syndromes in terms of the development of heart failure
[11,12]. Their diagnostic/prognostic usefulness is en-
hanced by other biomarkers such as troponin I and
C-reactive protein (CRP) [13]. However, these bio-
markers exhibit elevated levels also in patients with renal
failure, primary aldosteronism, congestive heart failure,
and thyroid disease [14]. There is, therefore, a need for
novel, more reliable, predictive biomarkers specific for
the development of HF.
The main aims of the present study were: (1) to estab-
lish alterations in gene expression patterns in leukocytes
associated with acute MI and through a follow-up; and
(2) to identify distinct biomarkers that correlate with HF
development.
Methods
Patients
Between the years 2010 and 2013, we studied consecu-
tive patients with ST elevation myocardial infarction
(STEMI) who were indicated for direct percutaneous
coronary interventions (PCI). The study group com-
prised n = 111 patients, who were admitted to the First
Chair and Department of Cardiology of the Medical
University of Warsaw, and the validation group com-
prised n = 41 patients admitted to the Department of
Cardiac Surgery and Department of Invasive Cardiology,
Medical University of Bialystok. All the patients underwentcoronary angiography and angioplasty of the infarct-related
artery. Pharmacological treatment was according to
current guidelines [15]. Participation in the study had
no influence on the pharmacological treatment and
the procedures the patients underwent. Patients from
the study and validation groups underwent echocardi-
ography and left ventricular ejection fractions (LVEF)
were calculated during hospitalization, 1 month, and 6
months after STEMI. Plasma NT-proBNP level was
measured on the first day of AMI (admission), after 4
to 6 days (discharge), and 6 months after AMI using
the Roche Diagnostics Elecsys® proBNP Immunoassay
(Roche, Mannheim, Germany). The withdrawal rate
was similar in both groups: for the study group n = 83
patients completed the study (75%), and for the valid-
ation group n = 32 (78%).
The aim of our analysis was to find expression of
genes linked specifically with MI and HF, not with cor-
onary artery disease (CAD). To exclude genes linked
with CAD we decided to take as a control group
patients with stable CAD, not healthy controls. The
blood samples were collected from n = 46 patients
(control I for study group) and n = 21 patients (control
II for validation group) with CAD proven using coron-
ary angiography (at least one stenosis exceeding 50%
or coronary angioplasty of a previous coronary artery
bypass graft) or non-invasive tests (positive exercise
test), and no history of myocardial infarction. NT-
proBNP and LVEF were measured in the control
group only on admission.
The STEMI patients from the study group who had a
myocardial infarction for the first time and volunteered
for a control visit 6 months after AMI were divided on
the basis of plasma NT-proBNP level and LVEF (mea-
sured 6 months after AMI) into four equal groups.
Among the patients from the first (Q1) and fourth (Q4)
quartiles we selected only those who had: a high level of
NT-proBNP and low LVEF 6 months after AMI (HF
group, n = 9 patients), or low level of NT-proBNP and
high LVEF 6 months after AMI (non-HF group, n = 8
patients).
The validation group comprised patients who had a
first myocardial infarction and volunteered for a control
visit 6 months after AMI. They were divided based on
the LVEF measurements into four equal groups. Patients
from the first (Q1) and fourth (Q4) quartile (low LVEF 6
months after AMI, HF patients, n = 7 and high LVEF 6
months after AMI, non-HF patients, n = 7, respectively),
were studied further.
The study was approved by the local Ethics Committees
of the Medical University of Warsaw and Medical Univer-
sity of Bialystok, and was conducted in accordance with the
principles of the Declaration of Helsinki. All participants
gave written informed consent.
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Whole blood samples were collected from the patients
at four time points: admission, discharge, after 1 month,
and after 6 months.
For the study group and control group I, peripheral
blood mononuclear cells (PBMCs) were isolated within
1 h of collection using BD Vacutainer® CPT™ Cell
Preparation Tubes with sodium citrate (Becton, Dickin-
son and Co., Franklin Lakes, NJ, USA) according to the
manufacturer’s instructions. Total RNA was isolated
from PBMCs with the MagNA Pure Compact System
(Roche Diagnostics GmbH, Germany) following the manu-
facturer’s recommendations.
For the validation and control group II, the PAXgene
Blood RNA system was used as it stabilizes RNA imme-
diately after sample collection and enables the storage of
samples for a relatively long period of time. Whole blood
was collected directly into PAXgene Blood RNA tubes
and total RNA was isolated within 24 h of collection
using the PAXgene Blood RNA kit (QIAGEN, Hilden,
Germany), following the manufacturer’s protocol.Figure 1 Outline of study design.RNA quantity was determined by UV absorption
(Nanodrop, LabTech International, UK). The quality of
RNA samples was checked using an Agilent 2100 Bioa-
nalizer© and RNA 6000 Nano Kit (Agilent, Santa Clara,
CA, USA). Samples with an RNA integrity number of 8
or above were considered suitable for use. RNA samples
were stored at -80°C until further analysis.
A schematic of patient cohorts and methodology is
shown in Figure 1.
cDNA microarrays
Preparation of labeled cDNA and hybridization to
GeneChip® Human Gene 1.0 ST arrays (Affymetrix,
Santa Clara, CA, USA) was performed according to the
manufacturer’s instructions. Briefly, a total of 100 ng of
RNA was reverse transcribed, amplified, and labeled
with biotin using the GeneChip® Whole Transcript
(WT) Sense Target Labeling Assay with included
quality control GeneChip® Hybridization Control Kits
(Affymetrix). Hybridization to the microarrays was
conducted for 16 h at 45°C. After hybridization the
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GeneChip Fluidics Station 450 and scanned on an
Affymetrix GCS 3000 GeneArray Scanner. The raw
microarray data reported in this manuscript have been
deposited in the Gene Expression Omnibus (GEO)
database with the accession number GSE59867.
Data analysis of microarrays
Quality control was conducted using the Affymetrix® Ex-
pression Console™ Software and standard Affymetrix
quality metrics. Raw microarray data were background
corrected, log transformed, and quantile normalized
using the robust multi-array average (RMA) algorithm
as implemented in the Partek® Genomics Suite™ software
(Partek Inc., St. Louis, MO, USA). The fold change (FC)
of gene expression ratios >1.3 and P <0.05 were set as
significance criteria to identify genes whose expression
was differentially regulated in the study group at four
time points. For transcriptional profiling in the HF and
non-HF groups, the significance criteria were set at FC
>1.5 and P <0.05. Probesets lacking annotation informa-
tion were removed from further analysis. Genes repre-
sented on microarrays by more than one probeset were
counted only once. Thus, the number of transcripts re-
fers to the number of unique genes.
To identify groups of functionally related genes, gene
ontology (GO) analysis was performed using the AmiGO's
Term Enrichment tool (version 1.8, [16]). The Ingenuity
Pathway Analysis (IPA) software (Ingenuity® Systems, [17])
was used to generate molecular interaction networks
and assess statistically relevant biofunctions and ca-
nonical pathways associated with the lists of differen-
tially expressed genes.
Quantitative real-time RT-PCR
The real-time reverse transcription-polymerase chain re-
action (RT-qPCR) was used to validate the microarray
results. Reverse transcription was carried out using total
RNA sample (200 ng from PBMCs, 800 ng from PAX)
and the QuantiTect Reverse Transcription kit (QIAGEN,
Hilden, Germany) according to the manufacturer's proto-
col. Primer sequences and reaction conditions are provided
in Additional file 1. Each sample was run in triplicate in
96-well plates using LightCycler®480 and LightCycler®480
FastStart SYBR Green I Master (Roche Diagnostics GmbH,
Germany). Quantification cycles (Cq) were calculated using
the second derivative method (LightCycler®480 Software,
Version 1.5 provided by Roche). The fold change of gene
expression levels, corrected by efficiency, was analyzed
using Relative Expression Software Tool (REST 2009) [18].
The expression data were normalized to the reference gene
HPRT1. All experiments (sample collection, preparation
and storage, primer design) were performed according to
the MIQE guidelines [19].Statistical methods
Statistical analysis was performed on R version 3.0.2
[20]. Continuous variables are presented as mean ±
standard deviation, categorical variables are reported as
frequencies and percentages. The distribution of con-
tinuous variables was first analyzed with the Shapiro-
Wilk test of normality and then, depending on the
results, the t-Student test, Mann-Whitney test, ANOVA or
Kruskal-Wallis test was applied. Categorical variables were
compared using Fisher’s exact test. The significance level
was set at 0.05.
To assess the discriminatory power of each marker, a
receiver operating characteristic (ROC) curve was con-
structed and the area under the curve (AUC) with 95%
confidence interval was calculated. The cutoff value for
each marker was defined as the marker fold change that
corresponds to the point on the ROC curve closest to
the point (0, 1). To assess monotonic association be-
tween expression levels of the biomarkers investigated
and HF development indicators, a Spearman’s rank cor-
relation coefficient and its P value were calculated for
each biomarker’s fold change-value on admission and
NT-proBNP and LVEF 6 months after AMI.
Results
Clinical characteristics of study groups
Patients presenting with STEMI, treated with primary per-
cutaneous revascularization, were enrolled in this study.
Their mean age ± SD was 58.8 ± 10.4 years and 61 ± 10.6
years for the study (n = 111) and the validation (n = 41)
groups, respectively. The baseline demographic and clinical
characteristics of the study and validation groups are
summarized in Table 1. Significant differences between
the two groups were observed for two parameters:
hypercholesterolemia was significantly more common
(P <0.001), and LVEF measured on admission was sig-
nificantly lower (P <0.001) in the validation compared
to the study group.
The characteristics of HF (n = 9) and non-HF (n = 8)
patients from the study group are given in Table 2, and
of the HF (n = 7) and non-HF patients (n = 7) from valid-
ation group in Table 3.
The baseline demographic and clinical characteristics
of the control groups are shown in Additional file 2.
Gene expression profiling at different time points
following AMI
To determine gene expression profiles and their possible
changes during the recovery from myocardial infarction,
we performed a transcriptome analysis in PBMCs iso-
lated from n = 111 AMI patients (study group) at four
time points, and from n = 46 CAD patients with no his-
tory of MI (control group I). Samples from the first three
time points (admission, discharge, and 1 month after
Table 1 Baseline demographic and clinical characteristics
of study and validation groups
Characteristics Study group
(n = 111)
Validation group
(n = 41)
P
value
Men 86 (77.5%) 31 (75.6%) 0.83
Women 25 (22.5%) 10 (24.4%) 0.83
Age (years) 58.8 ± 10.4 61 ± 10.6 0.277
BMI (kg/m2) 28.1 ± 4.7 28.9 ± 5.1 0.517
Hypertension 62 (55.9%) 28 (71.8%) 0.09
Diabetes 26 (23.4%) 6 (15.4%) 0.367
Previous MI 8 (7.2%) 3 (7.7%) 1
Smoking 54 (48.6%) 20 (51.3%) 0.853
Hypercholesterolemia 60 (54.1%) 34 (87.2%) <0.001
AMI 54 (51.4%) 17 (43.6%) 0.456
Previous
revascularization
3 (2.7%) 2 (5.1%) 0.605
Non-coronary
atherosclerosis
6 (5.4%) 3 (7.7%) 0.697
NT-proBNP (pg/mL) 1,641.4 ±
3,675.3
2,913.3 ± 6,975.7 0.559
LVEF (%) 49.3 ± 8.6 42.1 ± 8.3 <0.001
Medicationsa
Aspirin 105 (100%) 39 (100%) NA
Clopidogrel 104 (99%) 39 (100%) 1
Beta blockers 104 (99%) 38 (97.4%) 0.47
ACE inhibitors 100 (95.2%) 39 (100%) 0.324
Statins 103 (98.1%) 39 (100%) 1
Diuretics 21 (20%) 14 (35.9%) 0.079
aData were only available for n = 105 patients from the study group and n = 39
from validation group; these numbers were used to calculate percentages.
Data at admission.
Data are presented as mean value ± standard deviation or number or
percentage of patients. P value <0.05 was considered significant.
ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI,
body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Table 2 Baseline demographic and clinical characteristics
of HF, non-HF patients from study group
Characteristics HF patients
(n = 9)
Non-HF patients
(n = 8)
P value
Men 6 (66.7%) 7 (87.5%) 0.576
Women 3 (33.3%) 1 (12.5%) 0.576
Age (years) 60.1 ± 14.3 51.8 ± 7.2 0.147
BMI (kg/m2) 26.8 ± 3.1 25.6 ± 1.6 0.323
Hypertension 3 (33.3%) 1 (12.5%) 0.576
Diabetes 2 (22.2%) 1 (12.5%) >0.999
Previous MI 0 (0%) 0 (0%) NA
Smoking 3 (33.3%) 5 (62.5%) 0.347
Hypercholesterolemia 5 (55.6%) 4 (50%) >0.999
AMI 8 (88.9%) 3 (42.9%) 0.106
NT-proBNP (pg/mL)a 918.3 ± 848.5 62 ± 14.1 <0.001
LVEF (%)a 39.3 ± 8.4 66.8 ± 1.9 0.001
Medications
Aspirin 9 (100%) 8 (100%) NA
Clopidogrel 8 (88.9%) 8 (100%) >0.999
Beta blockers 9 (100%) 8 (100%) NA
ACE inhibitors 9 (100%) 8 (100%) NA
Statins 9 (100%) 8 (100%) NA
Diuretics 7 (77.8%) 1 (12.5%) 0.015
aNT-proBNP, LVEF measured 6 months after AMI.
Data are presented as mean value ± standard deviation or number or
percentage of patients. P value <0.05 was considered significant.
ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI,
body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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patients collected 6 months after AMI (stable phase),
which minimized the effects of inter-patient variability.
Additionally, a comparison between AMI samples and
samples from the control group was performed to iden-
tify genes shared between the comparisons. We identi-
fied 197 transcripts (153 up- and 44 downregulated) that
were differentially expressed on admission compared to
6 months after AMI (Additional file 3). Among them, 77
transcripts were also found to differ between admission
and the control group (Additional file 4). These tran-
scripts comprise an expression signature of the acute
phase of MI. On discharge 41 transcripts (40 up- and 1
downregulated) were differentially expressed compared
to 6 months after AMI (Additional file 5). Notably, most
of them encoded immunoglobulins. Similarly, transcripts
involved mainly in immune response were found todiffer between discharge and the control group. Twenty-
seven differentially expressed genes were common to
both comparisons (Additional file 6). One month after
AMI only two transcripts, both encoding immunoglobu-
lins (IGJ and IGKVI-33), were upregulated compared to
6 months after AMI (Additional file 7). IGJ was also
found to be expressed differentially between 1 month
after AMI and the control group.
A functional category analysis was carried out for
the transcripts differentially expressed in the acute
phase of MI (77 transcripts common to both analyses:
admission versus 6 months after AMI and admission
versus control). The gene ontology analysis using
AmiGO revealed that the molecular functions of these
transcripts were mainly associated with ‘protein bind-
ing’. The cellular component classification showed
that most of the differently expressed genes were in-
volved in both the extracellular region and the cell
membrane. The most significant biological processes
were ‘response to stimulus and stress’, ‘immune system
process (response and defense)’, and ‘single-organism
cellular process’ (Figure 2). The 77 transcripts were
also subjected to an interaction network analysis using
Table 3 Baseline demographic and clinical characteristics
of HF and non-HF patients from validation group
Characteristics HF patients
(n = 7)
Non-HF patients
(n = 7)
P value
Men 7 (100%) 7 (100%) NA
Women 0 (0%) 0 (0%) NA
Age (years) 59.7 ± 9.4 56.7 ± 13.2 0.634
BMI (kg/m2) 30 ± 3.7 26.1 ± 4.2 0.092
Hypertension 5 (71.4%) 5 (71.4%) 1
Diabetes 2 (28.6%) 0 (0%) 0.462
Previous MI 0 (0%) 0 (0%) NA
Smoking 3 (42.9%) 5 (71.4%) 0.592
Hypercholesterolemia 5 (71.4%) 5 (71.4%) 1
AMI 3 (42.9%) 2 (28.6%) 1
NT-proBNP (pg/mL)a 1,960.9 ± 3,421.9 119.4 ± 118.9 0.002
LVEF (%)a 28.9 ± 6.3 57.7 ± 4.7 <0.001
Medications
Aspirin 7 (100%) 7 (100%) NA
Clopidogrel 7 (100%) 7 (100%) NA
Beta blockers 7 (100%) 6 (85.7%) 1
ACE inhibitors 7 (100%) 7 (100%) NA
Statins 7 (100%) 7 (100%) NA
Diuretics 5 (71.4%) 1 (14.3%) 0.103
aNT-proBNP, LVEF measured 6 months after AMI.
Data are presented as mean value ± standard deviation or number or
percentage of patients. P value <0.05 was considered significant.
ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI,
body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarc-
tion; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Maciejak et al. Genome Medicine  (2015) 7:26 Page 6 of 15the IPA software. The results showed that 19 genes
(13 upregulated and 6 downregulated) were involved
in the top scoring network associated with ‘Cell-To-
Cell Signaling and Interaction, Hematological System
Development and Function, Immune Cell Trafficking’
(Figure 3).
Our previous pilot analysis on a cohort of n = 28 pa-
tients identified 24 genes as an expression signature of
the acute phase of MI [21]. It should be pointed out that
the differential expression of all those 24 transcripts was
confirmed in the current study on a substantially larger
group of patients when the reference were samples
from the same patients collected 6 months after AMI
(Additional file 3). When compared with the independ-
ent group of patients with no history of MI (control
group), 18 transcripts showed differential expression.
To confirm the robustness of the microarray results in
an independent cohort, mRNA levels of selected four
signature genes: aquaporin 9 (AQP9), family with se-
quence similarity 20, member A (FAM20A), and peroxi-
some proliferator-activated receptor gamma (PPARG),
suppressor of cytokine signaling 3 (SOCS3) were quanti-
fied by RT-qPCR using samples from the validationgroup (n = 41) collected at the same four time points
after AMI and from control group II (n = 21). The great-
est differences in expression were observed in the acute
phase after MI (admission vs. 6 months and admission
vs. control group II), and for all four genes the direction
and magnitude of the change agreed well with the
microarray data, as depicted in Tables 4 and 5. At the
next two time points (discharge and 1 month after AMI)
the differences in gene expression relative to that 6
months after AMI and to control group II were less
prominent, except for FAM20A. We stress here that the
gene expression changes detected using microarray ana-
lysis in PBMCs in the study group were validated here
using a different technique, an independent cohort, and
whole blood as the source of RNA. This shows that the
choice of material (whole blood vs. PBMCs) and analyt-
ical method (microarrays vs. RT-qPCR) does not affect
the obtained results, indicating the robustness of the
proposed approach.
Gene expression profiling in HF and non-HF groups
We attempted to identify transcripts whose differential
expression on the first day of myocardial infarction pre-
dicted which patients would develop symptoms of HF
during the 6 months of follow-up (Figure 4). For this
purpose, we compared the microarray results for sam-
ples collected on admission for the HF group versus the
non-HF group. A total of 127 transcripts showed signifi-
cant difference between the two groups (49 were up-
and 77 downregulated in HF patients) (Additional file 8).
We selected from control group I (with proven CAD
and no history of myocardial infarction) a random age-
matched subgroup of patients (n = 9) to perform an
additional microarray analysis. We compared the HF
group and the non-HF group with this control group
and from this comparison, we identified 256 transcripts
(155 up- and 101 downregulated) differentially expressed
in HF patients on admission and 58 transcripts (27 up-
and 31 downregulated) in non-HF patients on admission
(Additional files 9 and 10). Twenty transcripts were reg-
ulated similarly in the HF and non-HF patients, 236
transcripts (138 up- and 98 downregulated) were unique
to the HF group, and 38 transcripts (10 up- and 28
downregulated) to the non-HF group.
Functional analysis of the HF versus non-HF dataset
revealed that processes associated with immune response
and cell death were predominantly affected in HF patients.
‘Immune system process’, ‘apoptotic process’, and ‘pro-
grammed cell death’ were significantly overrepresented bio-
logical processes identified by AmiGO. The IPA analysis
indicated that three highest scoring networks are associated
with ‘humoral immune response’, ‘immunological disease’,
and ‘inflammatory disease’. The most significantly affected
canonical pathways were ‘iCOS-iCOSL signaling in T
Figure 2 Top enriched GO categories among genes differentially expressed on admission versus 6 months after AMI.
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ation’. In the ‘Molecular and Cellular Functions’ category
‘cell death and survival’, ‘cell-to-cell signaling and inter-
action’, and ‘cellular growth and function’ were the most
affected.
Based on individual microarray intensities for selected
genes (Additional file 11) and a systemic literature search
we selected for further studies four genes most significantly
differentiating the HF from non-HF patients: formin 1
(FMN1), Jun dimerization protein 2 (JDP2), ribonuclease,
RNase A family, 1 (pancreatic) (RNASE1), and TIMP
metallopeptidase inhibitor 1 (TIMP1). The selected bio-
markers are listed in Additional file 8. Changes in their ex-
pression levels were validated using quantitative RT-PCR
on the HF and non-HF samples from the study and valid-
ation groups. The results corroborated the microarray data.
For the RT-qPCR validation we used random age-matched
subgroups of patients with proven CAD but no MI (n = 9
in each), selected from the control groups I and II. Evalu-
ation of the HF and non-HF patients versus the appropriatecontrol groups by RT-qPCR did not confirm selective over-
expression of TIMP1 in HF patients from the study group.
Thus, TIMP1 was excluded from further analyses as a
potential prognostic biomarker. In the HF patients we ob-
served greater changes in gene expression of the selected
biomarkers than in non-HF patients (Table 6).
We measured gene expression levels of RNASE1,
JDP2, and FMN1 at the other time points after AMI
(4 to 6 days, 1 month, 6 months) in HF, non-HF, and
control groups from the study and validation groups
(Figure 5). In the comparison of HF versus non-HF pa-
tients and HF versus control groups the expression level
of selected biomarkers was significantly elevated on
admission both in the study and validation groups. In
the next time points after AMI we observed a gradual
decrease in expression between admission and 1 month,
and stabilization between 1 month and 6 months. In the
comparison of non-HF versus control groups we noted
only minor changes in the expression of the selected
transcripts.
Figure 3 Top scoring interaction network for 77 differentially expressed transcripts in the acute phase of MI. The network is classified as
‘Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking’. Genes or gene products are
represented as nodes, and the biological relationship between two nodes is represented as solid line (direct relationships) or dotted line (indirect
relationship). Upregulated and downregulated genes are shown in red and green shading, respectively, with color intensity related to the fold
change in expression.
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biomarkers associated with the progression of heart
failure
To determine the relationship between the level of ex-
pression of FMN1, JDP2, and RNASE1 upon AMI and
HF development Spearman’s rank correlation coeffi-
cients were calculated for the gene’s expression fold
change on admission and NT-proBNP and LVEF 6
months after AMI in the study and validation groups
(Table 7). The results showed a statistically significantmoderate positive monotonic correlation between each
biomarker’s fold-change value on admission and the
NT-proBNP level 6 months after AMI. A statistically
significant negative monotonic association between
RNASE1 and FMN1 fold-change value on admission and
LVEF 6 months after AMI was also found, and a non-
significant tendency for JDP2. Thus, an increase in the
biomarkers’ fold-change value on admission is related to
an increase in the NT-proBNP and a decrease in the
LVEF 6 months after AMI.
Table 4 RT-qPCR results for selected genes in validation group at different time points after AMI
Gene
symbol
Admission vs. 6 months Discharge vs. 6 months 1 month vs. 6 months
Microarray RT-qPCR Microarray RT-qPCR Microarray RT-qPCR
Study group Validation group Study group Validation group Study group Validation group
Fold
change
P value Fold
change
P value Fold
change
P value Fold
change
P value Fold
change
P value Fold
change
P value
AQP9 1.862 *** 1.580 *** 1.265 *** 1.158 ns 1.047 ns -1.046 ns
FAM20A 1.908 *** 4.283 *** 1.547 *** 3.104 *** 1.082 ns 1.015 ns
PPARG 1.613 *** 2.213 *** 1.144 *** 1.193 ns -1.012 ns -1.360 *
SOCS3 2.551 *** 1.794 *** 1.415 *** 1.177 ns 1.064 ns -1.144 ns
Statistical significance: *P <0.05. ***P <0.001.
Results were normalized to HPRT1.
ns, non-significant.
Maciejak et al. Genome Medicine  (2015) 7:26 Page 9 of 15To investigate the value of FMN1, JDP2, and RNASE1
as prognostic biomarkers of HF, the ROC analysis was
performed on the RT-qPCR data from n = 9 patients
with HF and n = 8 non-HF patients compared to the
control group n = 9. The analysis showed a good predict-
ive accuracy of those markers (Table 8 and Figure 6).
For RNASE1, the sensitivity was 77.8% and specificity
87.5% at a cutoff value of 3.1-fold change. For JDP2, at a
cutoff value of 1.7-fold change, these values were 88.9%
and 87.5%, respectively, and for FMN1 at a cutoff value
of 2.0-fold change - 66.7% and 100%. These results indi-
cate that the levels of expression of FMN1, JDP2, and
RNASE1 genes upon AMI are highly specific and sensi-
tive biomarkers for predicting HF.Discussion
In the present study we used gene expression profiling
in PBMCs to identify biologically relevant transcripts
significantly altered upon AMI and through the follow-
up. We further examined the changes in the gene ex-
pression profiles unique to patients who developed HF
after AMI and identified potential prognostic biomarkers
associated with the post-infarction LV remodeling.Table 5 RT-qPCR results for selected genes in validation grou
Gene
symbol
Admission vs. control group Discharge vs. co
Microarray RT-qPCR Microarray
Study group Validation group Study group
Fold
change
P value Fold
change
P value Fold
change
P valu
AQP9 1.622 *** 1.298 * 1.102 ns
FAM20A 1.704 *** 4.580 *** 1.382 *
PPARG 1.494 *** 1.753 ** 1.059 ns
SOCS3 1.840 *** 1.694 *** 1.020 ns
Statistical significance: *P <0.05. **P <0.01. ***P <0.001.
Results were normalized to HPRT1.
ns, non-significant.Transcriptional profiling is recently becoming a prom-
ising tool to study cardiovascular diseases [22-26]. The
most important limitation for accurate investigation of
the etiology and pathophysiology of HF is the necessity
for heart tissue sampling. It is not always possible to per-
form a biopsy in a patient with myocardial dysfunction
or damage. The use of blood as a surrogate tissue that
can be obtained with a minimally invasive procedure is
therefore an attractive alternative to cardiac biopsies.
While it may be argued that transcriptomic analysis of
cardiac tissues would more accurately picture the myo-
cardial response to MI, it is accepted that several cardio-
vascular conditions including coronary artery disease
[27] and chronic HF [28] are uniquely reflected by spe-
cific transcriptomic biosignatures in blood cells.
We have identified and characterized transcriptomic
signatures and pathways associated with AMI based on
gene expression analysis of PBMCs. Our previous [21]
and current results indicate that in the acute phase of
STEMI, dozens of genes from several pathways show al-
tered expression. Our results suggest that PBMCs are
activated in the acute phase of MI and gradually stabi-
lized during follow-up. Numerous studies found signifi-
cant roles of PBMCs in the systemic and regionalp in comparison with control group
ntrol group 1 month vs. control group
RT-qPCR Microarray RT-qPCR
Validation group Study group Validation group
e Fold
change
P value Fold
change
P value Fold
change
P value
-1.055 ns -1.095 ns -1.190 ns
3.288 *** -1.034 ns 1.165 ns
1.790 ** -1.093 ns -1.287 ns
1.097 ns -1.303 * -1.305 *
Figure 4 Outline of selection and distribution of patients from HF, non-HF, and control groups.
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acute MI [29-31]. Kim et al. [24] presented a subset of
genes associated with survival time after AMI in
Caucasian subjects with CAD. They also confirmed in a
large cohort that genes identified by us earlier [21] and
in this study as significantly associated with AMI corres-
pond very closely to the major component of AMI-
associated gene expression. Thus, activation of the
PBMCs, which reflects the magnitude of inflammation,
could be related with LV remodeling and even progres-
sion of MI patients.
A patient who has had an acute MI may or may not
progress to develop LV dysfunction and HF [32]. The
prognosis of patients after acute coronary syndrome
(ACS) largely depends on the extent of myocardial dam-
age during the acute phase. In the cohorts of nine pa-
tients from the study group and seven from the
validation group we observed that the future LV dys-
function had a specific biosignature in blood cells
already in the acute phase of MI. The identified tran-
scripts that differentiated on the first day of myocardial
infarction the HF patients from the non-HF ones and
the control group can serve as a novel tool contributing
to early prognosis and diagnosis of post-AMI patients.
This approach, validated in an independent cohort, may
also be useful in searching for the molecular predispos-
ition to the development of HF after AMI.
Our study indentified 127 transcripts significantly af-
fected in HF patients, of which three most promising
ones, FMN1, JDP2, and RNASE1 were analyzed further.
FMN1 belongs to the formin family of proteins. Ample
evidence suggests that most formins are effectors of
RhoA GTPase [33]. Some studies have demonstrated
that RhoA/ROCK has a major role in regulating actincytoskeleton organization, stress fiber formation, and
smooth muscle cell contraction [34]. Recent studies have
also demonstrated that the ROCK signaling pathway me-
diates the induction of cardiomyocyte hypertrophy [35].
We propose that the overexpression of FMN1 found in
our study may lead to the activation of RhoA/ROCK sig-
naling pathways implicating further development of car-
diac hypertrophy. Additionally, formins take part in the
promotion of adhesion and migration of inflammatory
cells - T cell and neutrophils - associated with the pro-
cesses taking place in the infarct scar during acute phase
MI and further left ventricular remodeling [36]. Rosado
et al. [37] examined the expression and localization pat-
terns of mammalian formins in cardiomyocytes and
found that numerous formins localize to the sarcomere,
the basic contractile unit of muscle fibers. Their distinct
patterns of expression, developmental recruitment into
the sarcomere, and subsarcomeric localization suggested
diverse roles of formins in the development and repair
of myofibrils. To the best of our knowledge, there is no
evidence for a direct role of FMN1 in the pathogenesis
of post-myocardial infarction HF. This is therefore a
novel biomarker that could lead to new insights into the
pathogenesis of HF.
The second gene/protein selected by us was JDP2, an
inhibitory component of the AP-1 transcription factor.
Several lines of evidence indicate an important role of
the AP-1 complex in cardiac development and function-
ing (reviewed in [38]). This includes the induction of im-
mune response cytokines and fetal gene expression in
the failing heart. Activation of AP-1 has been reported
in the early phase of myocardial infarction in the rat
[39], and in both experimental and human chronic
heart failure [40]. Transgenic mouse models with cardiac
Table 6 RT-qPCR results for selected genes in HF, non-HF, and control groups on admission
Gene
symbol
HF vs. non-HF HF vs. control group Non-HF vs. control group
Microarray RT-qPCR RT-qPCR Microarray RT-qPCR RT-qPCR Microarray RT-qPCR RT-qPCR
Study group Study group Validation group Study group Study group Validation group Study group Study group Validation group
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
Fold
change
P
value
FMN1 2.765 *** 2.173 * 1.843 * 3.081 *** 2.659 * 3.207 * 1.114 ns 1.223 ns 1.641 ns
JDP2 1.825 *** 1.823 ** 1.506 * 1.597 ** 2.548 *** 2.893 *** -1.142 ns 1.398 ** 1.933 **
RNASE1 2.044 ** 3.791 ** 3.007 * 2.612 *** 5.014 *** 6.362 *** 1.278 ns 1.323 ns 2.677 *
TIMP1 1.523 ** 1.498 ** 1.681 ** 1.421 ** -1.055 ns 2.250 ** -1.072 ns -1.580 ** 1.346 ns
Statistical significance: *P <0.05. **P <0.01. ***P <0.001.
Results were normalized to HPRT1.
ns, non-significant.
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Figure 5 Gene changes over time for investigated HF biomarkers in study and validation groups. Gene expression changes were
investigated in HF, non-HF, and control groups at different time points after AMI (on day 1, 4 to 6 days, 1 month, and 6 months) using RT-qPCR.
Red line: study group, black line: validation group. Data represent gene expression ratio ± standard error. The error bars are absent when smaller
than the size of the symbols. Statistical significance: *P <0.05; **P <0.01; ***P <0.001.
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and hypertrophy [41]. On the other hand, a recent study
on mouse ventricular cardiomyocytes under stimulation
with hypertrophy or apoptosis inducing agents has re-
vealed protective effects of JDP2 overexpression (and
thereby AP-1 inhibition) on ventricular remodeling [42].
Moreover, JDP2 has been found to induce (in association
with the Nrf2/MafK complex) several detoxifying orTable 7 Spearman’s rank correlation coefficients of
selected biomarkers fold-change and NT-proBNP and
LVEF values
Gene symbol NT-proBNP LVEF
FMN1 0.601 (P = 0.001) -0.468 (P = 0.009)
JDP2 0.417 (P = 0.023) -0.355 (P = 0.051)
RNASE1 0.566 (P = 0.001) -0.484 (P = 0.006)
Spearman’s rank correlation coefficients were calculated for the gene’s
expression fold change on admission and NT-proBNP and LVEF 6 months after
AMI in the study and validation groups.antioxidant enzymes protecting against reactive oxygen
species (ROS) [43]. It is well established that large
amounts of ROS are released in myocardial ischemia
and reperfusion. Given the reported data, one may
hypothesize that the increased JDP2 expression in the
blood of patients with a poor ventricular outcome after
MI is an adaptive response to the ischemic stress par-
ticularly profound in those patients. However, due to the
diversity of the biological processes affected by JDP2, a
comprehensive assessment of its role in cardiac remod-
eling remains to be established.
The third HF biomarker identified was RNASE1, a
member of the RNase A superfamily. In addition to their
ribonucleolytic activity, members of this superfamily
have other biological roles like host defense [44] and
angiogenesis [45]. It has been reported that human
RNase1 is synthesized not only in the pancreas, but is
also constitutively expressed and released by endothelial
cells. Based on its presence in the plasma and serum, it
has been proposed that RNase1 is expressed by vascular
Table 8 ROC curve analyses for FMN1, JDP2, and RNASE1
genes
Gene
symbol
AUC
(%)
95% CI
(%)
Cut-off value
(fold change)
Specificity
(%)
Sensitivity
(%)
FMN1 86.1 62.9-100 2 100 66.7
JDP2 83.3 60.5-100 1.7 87.5 88.9
RNASE1 87.5 69.4-100 3.1 87.5 77.8
AUC, area under the curve; CI, confidence interval; ROC, receiver
operating characteristic.
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(eRNA) [46]. The functions of eRNA in the vascular sys-
tem as proinflammatory and prothrombotic agents have
been shown to be neutralized by pancreatic type RNase1
[47]. eRNA released after local injury, ischemia/reperfusion
or oxidant stress increases the endothelial discharge of
RNase1, possibly protecting against the pro-inflammatory
effects of eRNA [48]. Application of ribonuclease 1 reduced
edema formation, lowered lesion volume in experimental
stroke [49], and also prevented atherogenesis [50]. Several
studies have employed large-scale gene expression analysis
to find novel pathophysiologically important genes involved
in the immune response and vascular injury. Moreover,
RNASE1 was among upregulated genes identified in a mul-
tiethnic patient cohort with a history of early MI [51].
These results support our findings that increased expres-
sion of RNASE1 can be part of the defense against pro-
inflammatory effects of eRNA following massive vascular
injury or tissue damage.
Our study is one of several recent attempts to identify
transcriptomic biomarkers of HF development in post-
AMI patients which may be helpful in understanding
the pathobiology of left ventricular remodeling and in
identifying biomarkers of individuals at high risk for the
development of HF. FMN1, JDP2, and RNASE1 partici-
pate in diverse processes activated under stress duringFigure 6 ROC curves for FMN1, JDP2, and RNASE1. AUC, area under theinjury. We postulate that the upregulation of these genes is
connected with the more severe initial damage to the heart
culminating later in HF. The receiver operating characteris-
tic analysis has indicated that these three transcripts are
likely to be good biomarkers with high sensitivity and speci-
ficity for HF prognosis and implicated in the course of LV
remodeling. Additionally, the validation in two independent
cohorts with the use of different blood collection tech-
niques has documented a high diagnostic accuracy of the
identified genes; nevertheless, further studies with larger pa-
tient groups are needed to prove unequivocally their value
as biomarkers of prospective heart failure.Study limitations
The major limitation of this study is the relatively small
patient groups with developed HF. Although the bio-
markers were verified on an independent group it will
be necessary to corroborate our findings on a larger co-
hort. The specificity and sensitivity of our biomarkers
were not tested against patients with other disease (for
example, primary aldosteronism, thyroid disease). Future
proof-of-concept studies are needed to confirm clinical
usefulness of the proposed biomarkers as a noninvasive
test for prognosis of HF development.Conclusions
This study demonstrated an altered gene expression pro-
file in PBMCs during acute myocardial infarction and
through the follow-up. We have identified a set of genes
whose expression on the first day of AMI differed sig-
nificantly between patients who developed HF during 6
months of observation and those who did not. The iden-
tified transcripts: FMN1, JDP2, and RNASE1 may serve
as novel prognostic biomarkers for the development of
HF after AMI.curve; ROC, receiver operating characteristic.
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